GlassScriptPhysician profile
Alyssa Aikman
NPI 1194348508
$3,319.00
in general payments reported to CMS, 2019-2025
18 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $586 · 2024: $1,120 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,131.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.48 | 2022-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $338.35 | 2022-2025 | Fanapt, Hetlioz |
| Corium, LLC | $245.59 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $242.33 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $236.26 | 2024-2025 | Rexulti |
| Lundbeck LLC | $214.09 | 2023-2025 | Rexulti |
| Alkermes, INC. | $186.73 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $173.43 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $170.14 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $163.45 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $149.26 | 2023-2025 | Ingrezza |
| Bausch Health US, LLC | $143.63 | 2024-2025 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $125.82 | 2024-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.59 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $67.34 | 2023-2024 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $63.51 | 2024 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $63.37 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $43.63 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Aikman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.